Cargando…

Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy

Detalles Bibliográficos
Autor principal:	O’Shaughnessy, Joyce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239505/ https://www.ncbi.nlm.nih.gov/pubmed/32436148 http://dx.doi.org/10.1007/s10549-020-05674-7

Ejemplares similares

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison
por: Rugo, Hope S., et al.
Publicado: (2023)

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer
por: Fasching, Peter A, et al.
Publicado: (2021)

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
por: O’Shaughnessy, Joyce, et al.
Publicado: (2017)

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
por: Edessa, Dumessa, et al.
Publicado: (2017)

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain
por: Galve-Calvo, Elena, et al.
Publicado: (2018)

Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
por: Jacobson, Anne
Publicado: (2022)

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women
por: Jeong, Eunae, et al.
Publicado: (2021)

Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective
por: Rosa, Daniela Dornelles, et al.
Publicado: (2022)

Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study
por: De Laurentiis, Michelino, et al.
Publicado: (2022)

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
por: Salvador Bofill, Javier, et al.
Publicado: (2022)

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
por: Neven, P., et al.
Publicado: (2023)

Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
por: Le, Vivian, et al.
Publicado: (2021)

Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis
por: Berrios, Kevin, et al.
Publicado: (2022)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
por: Yang, Jiangping, et al.
Publicado: (2020)

Ribociclib: a valuable addition to treatment options in breast cancer?
por: Bartsch, Rupert
Publicado: (2017)

Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
por: Bardia, Aditya, et al.
Publicado: (2021)

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Büyükkaramikli, Nasuh C., et al.
Publicado: (2018)

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
por: Verma, Sunil, et al.
Publicado: (2018)

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
por: Slamon, Dennis J., et al.
Publicado: (2023)

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
por: Odabas, Hatice, et al.
Publicado: (2023)

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
por: Hortobagyi, G N, et al.
Publicado: (2019)

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR(+)/HER2(−) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
por: Lu, Yen-Shen, et al.
Publicado: (2022)

Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
Publicado: (2023)

Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
por: Buehler, Anna Maria, et al.
Publicado: (2021)

Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program
por: Staropoli, Nicoletta, et al.
Publicado: (2022)

Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence
por: Alotaibi, Wedad H., et al.
Publicado: (2022)

Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2− Advanced Breast Cancer
por: Xie, Ning, et al.
Publicado: (2020)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
por: Porte, B., et al.
Publicado: (2020)

Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib
por: Sharaf, Baha’, et al.
Publicado: (2023)

Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection
por: Parati, Maria Chiara, et al.
Publicado: (2022)

Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer
por: Diao, Fei-Yu
Publicado: (2021)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
por: Stellato, Daniel, et al.
Publicado: (2021)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
por: Rugo, Hope S., et al.
Publicado: (2020)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?
por: Bilani, Nadeem, et al.
Publicado: (2022)

Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice
por: Rath, Sushmita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ars6oi8gnun75lbhdacbg80ohu